← All trials
NCT04956263
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2021
- Primary completion
- Dec 24, 2021
- Completion date
- Feb 16, 2022
- First posted
- Jul 9, 2021
- Last posted
- Nov 15, 2021
- Enrollment
- 18
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Youngene Therapeutics Inc., Ltd.Lead sponsor
- ProSciento, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.